

REPLACED SHEETS	SG
☒ Description : paged ...1... to paged ...7....	
☒ Claim(s) : paged ...8.... to paged ...9....	
☒ Drawing(s) : paged ...III.... to paged ...	
☒ Abstract : paged to paged	

I ANDRAL-ZIURYS Julia

of **ERNEST GUTMANN-YVES PLASSERAUD S.A.**
3, rue Chauveau-Lagarde
75008 PARIS (FRANCE)

declare that I am conversant with the French and
English languages and that to the best of my knowledge
and belief the following is a true translation of the text
of European Patent n° 92921684.4

Signature **ANDRAL-ZIURYS Julia**

J. Andral-Ziury

Paris, February 16, 1996

VIRAL RECOMBINANT VECTORS FOR EXPRESSION IN MUSCLE CELLS

The invention relates to recombinant vectors of viral origin which contain a nucleotide sequence coding for a specific polypeptide, and their use for the expression of this polypeptide in muscle cells. The invention also relates to a procedure for producing these vectors, as well as to their uses, in particular as medicines in the field of muscle diseases.

The hitherto unresolved problem of the direct diffusion of a gene towards a specific tissue is an obstacle to the development of gene therapy in the field of muscle diseases.

The various attempts to modify muscle tissue performed hitherto consist mainly of that involving fusion of muscle cells with a host cell (Salminen, A. et al., Hum. Gene Ther. 2, 15-26 (1991); Partridge, T.A. et al., Nature 337, 176-179 (1989), and that involving direct injection of DNA into the muscles (Wolff, J.A. et al., Science 247, 1465-1468 (1991); Acsadi, G., New Biol. 3, 71-81 (1991)).

The method proceeding by the fusion in mice of precursors of muscle cells derived from a normal donor with muscle fibers of a host (Partridge, T.A. et al., mentioned above) has been carried out with success and this cellular therapy has been the subject of preliminary trials in children. However, this approach seems to present too many disadvantages to be applicable to the treatment of muscle diseases. In fact, since the migratory capacities of the precursor cells are reduced to a few millimeters, the cellular implantation of these latter would necessitate millions of injections requiring hours of anaesthesia. Inevitably, there would be the risk of immunological problems leading to rejection phenomena occurring, as in the case of very many grafts. In addition, the treatment of Duchenne's muscular dystrophy (DMD) not only requires making contact with the skeletal muscles but also with the myocardial cells; the difficulties likely to be encountered in implanting precursors of muscle cells in the myocardium can easily be imagined. Consequently, cellular therapy hardly seems to be appropriate for the treatment of diseased cells showing such dissemination in the organism.

Gene therapy by direct in vivo introduction of nucleic acids into the interior of organs is an attractive method on account of its simplicity, but its development is confronted with a number of obstacles. In particular, the



expression of genes in the muscles remains localised at the site of injection (Wolff, J.A. et al., mentioned above) and seems to be of quite limited duration, particularly in cardiac muscle (Acsadi, G. et al., mentioned above).

The aim of the present invention is precisely to make possible the introduction of a very large number of nucleic acids into a considerable number of muscle cells (up to 50% or more) of a human or animal organism, whether these muscle cells be those of skeletal muscle or those of the myocardium.

The present invention relates more particularly to the transport of nucleic acids to target muscle cells by the blood, while protecting these nucleic acids against attack by various blood constituents.

Another aim of the present invention is to make available to the public pharmaceutical compositions which make possible the treatment of muscle diseases, and more particularly genetic diseases of the muscle system, or also diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleic acids, these products being secreted by the said muscle cells.

The present invention follows from the discovery made by the inventors of the fact that beta-galactosidase activity is found in many tissues after injection into mice of recombinant vectors of viral origin, more particularly of adenoviral origin, into the genome of which the gene coding for beta-galactosidase has been inserted. Such tissues include the lungs, liver, intestine, heart and the skeletal muscles. The expression of the gene for beta-galactosidase is constant with time, since the proportion of blue-coloured cells (colour obtained subsequent to gene expression) in the muscle tissue is more or less the same from one month to the next.

Figure 1 shows an example of the construction of a recombinant vector according to the invention and corresponding to a type Ad5 adenovirus, into the genome of which the gene for beta-galactosidase has been inserted under the control of the RSV promoter.

The subject of the present invention is the use of recombinant vectors of viral origin, incapable of replication and likely to be recognized by the receptors of human and animal muscle cell which can be infected by these viruses, these vectors being additionally modified by a nucleic acid insert containing a nucleotide sequence which codes for a polypeptide sequence, the expression of which in the said muscle cells is sought, this sequence being under the control of a promoter recognized by the



polymerases of these cells, for the production of drug compositions which can be administered by the general route, particularly the intravenous or intraarterial route, and designed for the treatment of either diseases affecting muscle cells or diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleic acids and secreted by the said muscle cells.

The adenoviruses, in particular the human adenoviruses type 2 or 5 represent particularly preferred vectors in the framework of the present invention by virtue in particular of the large size of the foreign DNA fragment which it is possible to insert into the genome of these viruses.

Advantageously, the above-mentioned nucleic acid insert is included in a defective genome of an adenovirus, this genome lacking essential sequences necessary for the replication of these adenoviruses, and more particularly the EA and EB transactivators; nonetheless, this genome preferentially includes all of those essential sequences necessary for the encapsidation of these adenoviruses.

The promoter used may be an endogenous promoter (for example, an early or late promoter of the adenovirus used) or an exogenous promoter.

It will be advantageous to have recourse to strong promoters, for example one having about the same strength as the promoter contained in the LTR (Long Terminal Repeat) of RSV (Rous Sarcoma Virus).

As examples of other promoters whose use may be considered, mention should be made of :

- the promoter of the IE gene of CMV (cytomegalovirus)
- the MMTV (Mouse Mammary tumor Virus) inducible promoters or metallothionein promoters.

The strength of the promoter which is used may be estimated in assays similar to those which are described in the examples which follow, for example by replacing the promoter under study in the vectors of these examples by the promoter contained in the LTR of RSV and by the evaluation of the intensity of expression of the marker obtained, an intensity which can then be compared with that obtained with the promoter of LTR of RSV.

The amount of vectors administered to the organism is advantageously chosen so as to overwhelm the immune system of the organism into which they are injected



Advantageously, the route of administration selected in the framework of the present invention is the intravenous or intraarterial route.

Among the diseases affecting muscle cells mentioned above, mention may be made of genetic diseases such as muscular dystrophy.

Consequently, the nucleic acid inserted into the genome of the viral vector and the diffusion of which into the muscle mass is desired, comprises a nucleotide sequence coding for a polypeptide capable of treating the disease in question, and more particularly of playing the role in the muscle cell of the polypeptide normally present in a healthy cell, but the deficiency of which is due either to an abnormally low level or the complete failure of the production of this polypeptide, or to an error in its amino acid sequence which results from genetic anomalies in its coding nucleotide sequence.

Vectors according to the invention used to produce a medicine designed for the treatment of muscular dystrophy are more particularly characterized in that the nucleic acid insert is constituted by all or part of a healthy gene for dystrophin. The introduction of the entire gene for dystrophin or even of any part of this gene which codes for a polypeptide conserving an activity similar to that of the whole protein can be carried out in accordance with a method identical with that described hereafter for the introduction of the gene for beta-galactosidase.

As examples of diseases other than muscle diseases, susceptible to treatment in the framework of the present invention, mention may be made of the thromboses originating from infarctuses or also phlebitis.

Vectors according to the invention used to produce a drug designed for the treatment of thromboses and for the prevention of infarctus and phlebitis are more particularly characterized in that the nucleic acid insert comprises a nucleotide sequence coding for a thrombolytic substance. The latter sequence is advantageously preceded by a signal sequence which codes for a peptide signal which ensures the secretion of the thrombolytic substance outside the muscle cell.

The invention also relates to any recombinant vector characterized in that it is constituted of the defective genome of an adenovirus comprising, nonetheless, all of the essential sequences necessary for the encapsidation of this adenovirus, and into which is inserted a recombinant nucleic acid, the diffusion of which is desired in the muscle mass, this nucleic acid being placed under the control of a promoter capable of being recognized by the



polymerases of the muscle cells, in particular by the strong promoter of the E1A early region of the genome of the adenoviruses.

A preferred recombinant vector of the invention is characterized in that this recombinant nucleic acid is constituted by all or part of the gene for dystrophin.

The invention also relates to pharmaceutical compositions consisting one or more recombinant vectors such as those described above, in combination with a pharmaceutically acceptable vehicle.

The subject of the invention is also a procedure for producing the recombinant vectors described above which comprises, after the construction stage itself of these vectors by the introduction of the nucleic acid insert into their genome, a transformation step of transformable cell lines of higher eukaryotes (particularly of human or animal origin), themselves carrying a distinct nucleotide sequence capable of complementing the part of the genome of the adenovirus essential for the replication thereof and which the above-mentioned vector lacks, the said distinct sequence being preferably incorporated into the genome of the cells of the said cell line.

As a preferred example of such cell lines, mention should be made of line 293, a human embryonic kidney line which contains, integrated into its genome, the first eleven percent of the lefthand end of the genome of an Ad5. This portion complements defective recombinant viruses which bear deletions in this region. Such a production procedure is more particularly described in the European patent application No. 0 185 573 of 20/11/85.

After transformation of these cell lines, the vectors which are thus multiplied are recovered and purified.

The present invention will be illustrated more particularly with the aid of the detailed description which follows of the construction of recombinant adenovirus vectors comprising the gene coding for beta-galactosidase, and of the properties of this adenovirus vector.

1. Construction of the recombinant adenovirus, Ad-RSV-beta-gal, by means of in vivo recombination.

This recombinant adenovirus was constructed by homologous recombination between a suitable plasmid and the genome of a type 5 (Ad5) adenovirus. In this construction, the gene for beta-galactosidase is placed under the control of the RSV (Rous Sarcoma Virus) promoter. The plasmid pAdRSV ' β gal' contains the PvuII segment of the lefthand end of the Ad5 (segment situated between the positions 0 and 1.3 of the



plasmid in Figure 1) comprising the inverted terminal repeat, the origin of replication, encapsidation signals and the amplifier *Ela*. This fragment is followed by a *nlslacZ* gene (described in Bonnerot, C. et al., Proc. Natl. Acad. Sci. USA, 1987, 84, 6795-6799) which codes for beta-galactosidase, and by a fragment of the adenovirus Ad5 situated between the positions 9.4 and 17 of the plasmid of Figure 1.

The values of the positions 1.3, 9.4 and 17 indicated above are units indicating the number of base pairs included within these fragments, one unit representing 360 base pairs.

The Ad5 sequence situated between the above-mentioned positions 9.4 and 17 allows recombination with the adenovirus dl324 treated by the restriction enzyme *ClaI* (corresponding to a deletion mutant E3; the deletion being made between the positions 78.4 and 84.3 of the genome of the adenovirus shown in Figure 1), after transfection of 293 cells (human embryonic kidney cells transformed by the adenovirus and mentioned above) in order to generate the recombinant vector Ad-RSV-betagal. The *nlslacZ* gene is controlled by the RSV LTR promoter and possesses the polyadenylation signal of the SV40 virus. The recombinant virus thus obtained is incapable of replicating on account of the deletion of the E1 genes.

2. Study of the transfer of the gene to the organs of the mouse through the intermediary of the adenovirus.

Four day old Balb/C mice are given an intravenous injection of 20-40 microliters of highly purified recombinant adenovirus Ad-RSV-betagal (10^9 plaque-forming units : PFU/ml), the organs were excised 15 days after the injection and treated with 4% paraformaldehyde in a phosphate buffer for 30 minutes. After being rinsed, the organs were incubated overnight at 30°C in a X-gal solution. The whole organs were then frozen and treated appropriately so that cryosections (10 micrometers thick) could be prepared and these sections were stained with the aid of hematoxylin and eosin.

The demonstration by means of histochemical staining in the manner indicated above of beta-galactosidase activity in the sections prepared indicates the presence of the gene inserted into the adenovirus vector. in the cells of the excised organs.

The macroscopic examination of the heart as well as the skeletal muscles excised from these treated mice reveals the great efficiency with which this gene transfer was made after only one injection of the recombinant



adenovirus. The significance of the choice of the intravenous route resides in the fact that the viral vector is not concentrated in any particular zone of the muscle tissue but, conversely, it is favourably distributed throughout the muscle mass. The histochemical staining leads to estimates that the number of transformed cells in some zones attains as much as 50% of the number of muscle cells present in this zone.

The expression of beta-galactosidase in the myocardium as well as in the skeletal muscles is perfectly stable. It was possible to observe positive stains 15, 33, 55, 66, 90, 127 and 150 days after the injection of the recombinant adenovirus. The expression of the gene seems to be constant as a function of time since the proportion of blue cells in the muscle tissues seem to be more or less the same from one month to the next.

The analysis of isolated muscle fibers reveals that a single fiber is likely to offer many "centers of expression".

Analyses by (Southern) immunoblot performed on the heart of a treated mouse have led to the demonstration of an intense and unique band at 35 kbp indicating that the viral DNA introduced into the muscle cells is essentially extrachromosomal.

This Sheet Has Been Replaced



This Sheet Has Been Replaced



CLAIMS

1. Use of recombinant vectors of viral origin, incapable of replication and capable of being recognized by the receptors of human and animal muscle cells which can be infected with these viruses, these viruses being in addition modified by a nucleic acid insert containing a nucleotide sequence coding for a polypeptide sequence, the expression of which in the said muscle cells is sought this sequence being under the control of a promoter recognized by the polymerases of these cells for the production of a drug composition which can be administered by the general route, in particular the intravenous or intraarterial route, and is designed for the treatment of either diseases affecting the muscle cells or diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleotide sequence secreted by said muscle cells.
2. Use of vectors according to Claim 1, characterized in that these vectors are selected from defective adenoviruses, the genomes of which lack essential sequences necessary for the replication of these adenoviruses, and more particularly the EA and EB transactivators.
3. Use of vectors according to Claim 1 or Claim 2, characterized in that the nucleic acid insert is included in a defective adenovirus genome comprising nonetheless all of the essential sequences necessary for the encapsidation of these adenoviruses.
4. Use of vectors according to one of the Claims 1 to 3, characterized in that the nucleic acid insert is constituted by all or part of a healthy gene for dystrophin.
5. Use of vectors according to one of the Claims 1 to 4 for the production of a medicine designed for the treatment of Duchenne's muscular dystrophy.
6. Use of vectors according to any one of the Claims 1 to 3 for the production of drug compositions for the treatment of cardiac diseases, characterized in that the nucleic acid insert codes for a protein or polypeptide having thrombolytic properties.
7. Recombinant vector characterized in that it is constituted by a defective genome of an adenovirus, nonetheless comprising all of the essential sequences necessary for the encapsidation of this adenovirus, and in which is inserted a recombinant nucleic acid, the diffusion of which into the



muscle mass is sought, this nucleic acid being placed under the control of a promoter capable of being recognized by the polymerases of the muscle cells, in particular the strong promoter of the E1A early region of the genome of the adenoviruses.

8. Recombinant vector according to Claim 7, characterized in that the nucleic acid insert codes for a protein or polypeptide having thrombolytic properties.

9. Pharmaceutical composition containing a recombinant vector according to Claim 7 or Claim 8, in combination with a pharmaceutically acceptable vehicle.

This Sheet Has Been Replaced



ABSTRACT

VIRAL RECOMBINANT VECTORS FOR EXPRESSION IN MUSCLE CELLS


Non-replicable viral recombinant vectors which are recognizable by muscle cell receptors, and furthermore modified by an insertion nucleic acid coding for a polypeptide sequence to be expressed in said muscle cell, are used to obtain a drug for treating muscle cell diseases or diseases which by virtue of their location in the body, are accessible to the products of the expression of the above mentioned nucleotide sequence, as secreted by said muscle cells. A method for producing said vectors, vectors such as those described above, and their use in pharmaceutical compositions are also provided.

This Sheet Has Been Replaced



1 / 1

FIGURE 1



This Sheet Has Been Replaced



FEUILLE DE REMPLACEMENT



3 1 OCT 1996

VIRAL RECOMBINANT VECTORS FOR EXPRESSION IN MUSCLE CELLS

The invention relates to recombinant vectors of viral origin which contain a nucleotide sequence coding for a specific polypeptide, and their use for the expression of this polypeptide in muscle cells. The invention also relates to a procedure for producing these vectors, as well as to their uses, in particular as medicines in the field of muscle diseases.

The hitherto unresolved problem of the direct diffusion of a gene towards a specific tissue is an obstacle to the development of gene therapy in the field of muscle diseases.

The various attempts to modify muscle tissue performed hitherto consist mainly of that involving fusion of muscle cells with a host cell (Salminen, A. et al., Hum. Gene Ther. 2, 15-26 (1991); Partridge, T.A. et al., Nature 337, 176-179 (1989), and that involving direct injection of DNA into the muscles (Wolff, J.A. et al., Science 247, 1465-1468 (1991); Acsadi, G., New Biol. 3, 71-81 (1991)).

The method proceeding by the fusion in mice of precursors of muscle cells derived from a normal donor with muscle fibers of a host (Partridge, T.A. et al., mentioned above) has been carried out with success and this cellular therapy has been the subject of preliminary trials in children. However, this approach seems to present too many disadvantages to be applicable to the treatment of muscle diseases. In fact, since the migratory capacities of the precursor cells are reduced to a few millimeters, the cellular implantation of these latter would necessitate millions of injections requiring hours of anaesthesia. Inevitably, there would be the risk of immunological problems leading to rejection phenomena occurring, as in the case of very many grafts. In addition, the treatment of Duchenne's muscular dystrophy (DMD) not only requires making contact with the skeletal muscles but also with the myocardial cells; the difficulties likely to be encountered in implanting precursors of muscle cells in the myocardium can easily be imagined. Consequently, cellular therapy hardly seems to be appropriate for the treatment of diseased cells showing such dissemination in the organism.

Gene therapy by direct in vivo introduction of nucleic acids into the interior of organs is an attractive method on account of its simplicity, but its development is confronted with a number of obstacles. In particular, the

31 OCT 1996

expression of genes in the muscles remains localised at the site of injection (Wolff, J.A. et al., mentioned above) and seems to be of quite limited duration, particularly in cardiac muscle (Acsadi, G. et al., mentioned above).

The aim of the present invention is precisely to make possible the introduction of a very large number of nucleic acids into a considerable number of muscle cells (up to 50% or more) of a human or animal organism, whether these muscle cells be those of skeletal muscle or those of the myocardium.

The present invention relates more particularly to the transport of nucleic acids to target muscle cells by the blood, while protecting these nucleic acids against attack by various blood constituents.

Another aim of the present invention is to make available to the public pharmaceutical compositions which make possible the treatment of muscle diseases, and more particularly genetic diseases of the muscle system, or also diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleic acids, these products being secreted by the said muscle cells.

The present invention follows from the discovery made by the inventors of the fact that beta-galactosidase activity is found in many tissues after injection into mice of recombinant vectors of viral origin, more particularly of adenoviral origin, into the genome of which the gene coding for beta-galactosidase has been inserted. Such tissues include the lungs, liver, intestine, heart and the skeletal muscles. The expression of the gene for beta-galactosidase is constant with time, since the proportion of blue-coloured cells (colour obtained subsequent to gene expression) in the muscle tissue is more or less the same from one month to the next.

Figure 1 shows an example of the construction of a recombinant vector according to the invention and corresponding to a type Ad5 adenovirus, into the genome of which the gene for beta-galactosidase has been inserted under the control of the RSV promoter.

The subject of the present invention is the use of recombinant vectors of viral origin, incapable of replication and likely to be recognized by the receptors of human and animal muscle cell which can be infected by these viruses, these vectors being additionally modified by a nucleic acid insert containing a nucleotide sequence which codes for a polypeptide sequence, the expression of which in the said muscle cells is sought, this sequence being under the control of a promoter recognized by the



polymerases of these cells, for the production of drug compositions which can be administered by the general route, particularly the intravenous or intraarterial route, and designed for the treatment of either diseases affecting muscle cells or diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleic acids and secreted by the said muscle cells.

The adenoviruses, in particular the human adenoviruses type 2 or 5 represent particularly preferred vectors in the framework of the present invention by virtue in particular of the large size of the foreign DNA fragment which it is possible to insert into the genome of these viruses.

Advantageously, the above-mentioned nucleic acid insert is included in a defective genome of an adenovirus, this genome lacking essential sequences necessary for the replication of these adenoviruses, and more particularly the EA and EB transactivators; nonetheless, this genome preferentially includes all of those essential sequences necessary for the encapsidation of these adenoviruses.

The promoter used may be an endogenous promoter (for example, an early or late promoter of the adenovirus used) or an exogenous promoter.

It will be advantageous to have recourse to strong promoters, for example one having about the same strength as the promoter contained in the LTR (Long Terminal Repeat) of RSV (Rous Sarcoma Virus).


As examples of other promoters whose use may be considered, mention should be made of :

- the promoter of the IE gene of CMV (cytomegalovirus)
- the MMTV (Mouse Mammary umor Virus) inducible promoters or metallothionine promoters.

The strength of the promoter which is used may be estimated in assays similar to those which are described in the examples which follow, for example by replacing the promoter under study in the vectors of these examples by the promoter contained in the LTR of RSV and by the evaluation of the intensity of expression of the marker obtained, an intensity which can then be compared with that obtained with the promoter of LTR of RSV.

The amount of vectors administered to the organism is advantageously chosen so as to overwhelm the immune system of the organism into which they are injected

This Sheet Has Been Replaced



Advantageously, the route of administration selected in the framework of the present invention is the intravenous or intraarterial route.

Among the diseases affecting muscle cells mentioned above, mention may be made of genetic diseases such as muscular dystrophy.


Consequently, the nucleic acid inserted into the genome of the viral vector and the diffusion of which into the muscle mass is desired, comprises a nucleotide sequence coding for a polypeptide capable of treating the disease in question, and more particularly of playing the role in the muscle cell of the polypeptide normally present in a healthy cell, but the deficiency of which is due either to an abnormally low level or the complete failure of the production of this polypeptide, or to an error in its amino acid sequence which results from genetic anomalies in its coding nucleotide sequence.

Vectors according to the invention used to produce a medicine designed for the treatment of muscular dystrophy are more particularly characterized in that the nucleic acid insert is constituted by all or part of a healthy gene for dystrophin. The introduction of the entire gene for dystrophin or even of any part of this gene which codes for a polypeptide conserving an activity similar to that of the whole protein can be carried out in accordance with a method identical with that described hereafter for the introduction of the gene for beta-galactosidase.

As examples of diseases other than muscle diseases, susceptible to treatment in the framework of the present invention, mention may be made of the thromboses originating from infarctuses or also phlebitis.

Vectors according to the invention used to produce a drug designed for the treatment of thromboses and for the prevention of infarctus and phlebitis are more particularly characterized in that the nucleic acid insert comprises a nucleotide sequence coding for a thrombolytic substance. The latter sequence is advantageously preceded by a signal sequence which codes for a peptide signal which ensures the secretion of the thrombolytic substance outside the muscle cell.

The invention also relates to any recombinant vector characterized in that it is constituted of the defective genome of an adenovirus comprising, nonetheless, all of the essential sequences necessary for the encapsidation of this adenovirus, and into which is inserted a recombinant nucleic acid, the diffusion of which is desired in the muscle mass, this nucleic acid being placed under the control of a promoter capable of being recognized by the



This Sheet Has Been Replaced



polymerases of the muscle cells, in particular by the strong promoter of the E1A early region of the genome of the adenoviruses.

A preferred recombinant vector of the invention is characterized in that this recombinant nucleic acid is constituted by all or part of the gene for dystrophin.

The invention also relates to pharmaceutical compositions consisting one or more recombinant vectors such as those described above, in combination with a pharmaceutically acceptable vehicle.

The subject of the invention is also a procedure for producing the recombinant vectors described above which comprises, after the construction stage itself of these vectors by the introduction of the nucleic acid insert into their genome, a transformation step of transformable cell lines of higher eukaryotes (particularly of human or animal origin), themselves carrying a distinct nucleotide sequence capable of complementing the part of the genome of the adenovirus essential for the replication thereof and which the above-mentioned vector lacks, the said distinct sequence being preferably incorporated into the genome of the cells of the said cell line.

As a preferred example of such cell lines, mention should be made of line 293, a human embryonic kidney line which contains, integrated into its genome, the first eleven percent of the lefthand end of the genome of an Ad5. This portion complements defective recombinant viruses which bear deletions in this region. Such a production procedure is more particularly described in the European patent application No. 0 185 573 of 20/11/85.

After transformation of these cell lines, the vectors which are thus multiplied are recovered and purified.

The present invention will be illustrated more particularly with the aid of the detailed description which follows of the construction of recombinant adenovirus vectors comprising the gene coding for beta-galactosidase, and of the properties of this adenovirus vector.

1. Construction of the recombinant adenovirus, Ad-RSV-beta-gal, by means of in vivo recombination.

This recombinant adenovirus was constructed by homologous recombination between a suitable plasmid and the genome of a type 5 (Ad5) adenovirus. In this construction, the gene for beta-galactosidase is placed under the control of the RSV (Rous Sarcoma Virus) promoter. The plasmid pAdRSV ' β gal' contains the PvuII segment of the lefthand end of the Ad5 (segment situated between the positions 0 and 1.3 of the



plasmid in Figure 1) comprising the inverted terminal repeat, the origin of replication, encapsidation signals and the amplifier *Ela*. This fragment is followed by a *nlslacZ* gene (described in Bonnerot, C. et al., Proc. Natl. Acad. Sci. USA, 1987, 84, 6795-6799) which codes for beta-galactosidase, and by a fragment of the adenovirus Ad5 situated between the positions 9.4 and 17 of the plasmid of Figure 1.

The values of the positions 1.3, 9.4 and 17 indicated above are units indicating the number of base pairs included within these fragments, one unit representing 360 base pairs.

The Ad5 sequence situated between the above-mentioned positions 9.4 and 17 allows recombination with the adenovirus dl324 treated by the restriction enzyme *Clal* (corresponding to a deletion mutant E3; the deletion being made between the positions 78.4 and 84.3 of the genome of the adenovirus shown in Figure 1), after transfection of 293 cells (human embryonic kidney cells transformed by the adenovirus and mentioned above) in order to generate the recombinant vector Ad-RSV-betagal. The *nlslacZ* gene is controlled by the RSV LTR promoter and possesses the polyadenylation signal of the SV40 virus. The recombinant virus thus obtained is incapable of replicating on account of the deletion of the E1 genes.

2. Study of the transfer of the gene to the organs of the mouse through the intermediary of the adenovirus.

Four day old Balb/C mice are given an intravenous injection of 20-40 microliters of highly purified recombinant adenovirus Ad-RSV-betagal (10^9 plaque-forming units : PFU/ml), the organs were excised 15 days after the injection and treated with 4% paraformaldehyde in a phosphate buffer for 30 minutes. After being rinsed, the organs were incubated overnight at 30°C in a X-gal solution. The whole organs were then frozen and treated appropriately so that cryosections (10 micrometers thick) could be prepared and these sections were stained with the aid of hematoxylin and eosin.

The demonstration by means of histochemical staining in the manner indicated above of beta-galactosidase activity in the sections prepared indicates the presence of the gene inserted into the adenovirus vector. in the cells of the excised organs.

The macroscopic examination of the heart as well as the skeletal muscles excised from these treated mice reveals the great efficiency with which this gene transfer was made after only one injection of the recombinant

REPLACEMENT SHEET

31 OCT 1996

This Sheet Has Been Replaced




adenovirus. The significance of the choice of the intravenous route resides in the fact that the viral vector is not concentrated in any particular zone of the muscle tissue but, conversely, it is favourably distributed throughout the muscle mass. The histochemical staining leads to estimates that the number of transformed cells in some zones attains as much as 50% of the number of muscle cells present in this zone.

The expression of beta-galactosidase in the myocardium as well as in the skeletal muscles is perfectly stable. It was possible to observe positive stains 15, 33, 55, 66, 90, 127 and 150 days after the injection of the recombinant adenovirus. The expression of the gene seems to be constant as a function of time since the proportion of blue cells in the muscle tissues seem to be more or less the same from one month to the next.

The analysis of isolated muscle fibers reveals that a single fiber is likely to offer many "centers of expression".


Analyses by (Southern) immunoblot performed on the heart of a treated mouse have led to the demonstration of an intense and unique band at 35 kbp indicating that the viral DNA introduced into the muscle cells is essentially extrachromosomal.



This Sheet Has Been Replaced



This Sheet Has Been Replaced



CLAIMS

1. Use of recombinant vectors of viral origin, incapable of replication and capable of being recognized by the receptors of human and animal muscle cells which can be infected with these viruses, these viruses being in addition modified by a nucleic acid insert containing a nucleotide sequence coding for a polypeptide sequence, the expression of which in the said muscle cells is sought this sequence being under the control of a promoter recognized by the polymerases of these cells for the production of a drug composition which can be administered by the general route, in particular the intravenous or intraarterial route, and is designed for the treatment of either diseases affecting the muscle cells or diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleotide sequence secreted by said muscle cells.
2. Use of vectors according to Claim 1, characterized in that these vectors are selected from defective adenoviruses, the genomes of which lack essential sequences necessary for the replication of these adenoviruses, and more particularly the EA and EB transactivators.
3. Use of vectors according to Claim 1 or Claim 2, characterized in that the nucleic acid insert is included in a defective adenovirus genome comprising nonetheless all of the essential sequences necessary for the encapsidation of these adenoviruses.
4. Use of vectors according to one of the Claims 1 to 3, characterized in that the nucleic acid insert is constituted by all or part of a healthy gene for dystrophin.
5. Use of vectors according to one of the Claims 1 to 4 for the production of a medicine designed for the treatment of Duchenne's muscular dystrophy.
6. Use of vectors according to any one of the Claims 1 to 3 for the production of drug compositions for the treatment of cardiac diseases, characterized in that the nucleic acid insert codes for a protein or polypeptide having thrombolytic properties.
7. Recombinant vector characterized in that it is constituted by a defective genome of an adenovirus, nonetheless comprising all of the essential sequences necessary for the encapsidation of this adenovirus, and in which is inserted a recombinant nucleic acid, the diffusion of which into the







muscle mass is sought, this nucleic acid being placed under the control of a promoter capable of being recognized by the polymerases of the muscle cells, in particular the strong promoter of the E1A early region of the genome of the adenoviruses.

8. Recombinant vector according to Claim 7, characterized in that the nucleic acid insert codes for a protein or polypeptide having thrombolytic properties.

9. Pharmaceutical composition containing a recombinant vector according to Claim 7 or Claim 8, in combination with a pharmaceutically acceptable vehicle.



ABSTRACT

VIRAL RECOMBINANT VECTORS FOR EXPRESSION IN MUSCLE CELLS

Non-replicatable viral recombinant vectors which are recognizable by muscle cell receptors, and furthermore modified by an insertion nucleic acid coding for a polypeptide sequence to be expressed in said muscle cell, are used to obtain a drug for treating muscle cell diseases or diseases which by virtue of their location in the body, are accessible to the products of the expression of the above mentioned nucleotide sequence, as secreted by said muscle cells. A method for producing said vectors, vectors such as those described above, and their use in pharmaceutical compositions are also provided.

Figure 1






FIGURE 1



REPLACEMENT SHEET

3 1 OCT 1996

This Sheet Has Been Replaced



VIRAL RECOMBINANT VECTORS FOR EXPRESSION IN MUSCLE CELLS

The invention relates to recombinant vectors of viral origin which contain a nucleotide sequence coding for a specific polypeptide, and their use for the expression of this polypeptide in muscle cells. The invention also relates to a procedure for producing these vectors, as well as to their uses, in particular as medicines in the field of muscle diseases.

The hitherto unresolved problem of the direct diffusion of a gene towards a specific tissue is an obstacle to the development of gene therapy in the field of muscle diseases.

The various attempts to modify muscle tissue performed hitherto consist mainly of that involving fusion of muscle cells with a host cell (Salminen, A. et al., Hum. Gene Ther. 2, 15-26 (1991); Partridge, T.A. et al., Nature 337, 176-179 (1989), and that involving direct injection of DNA into the muscles (Wolff, J.A. et al., Science 247, 1465_1468 (1991); Acsadi, G., New Biol. 3, 71-81 (1991)).

The method proceeding by the fusion in mice of precursors of muscle cells derived from a normal donor with muscle fibers of a host (Partridge, T.A. et al., mentioned above) has been carried out with success and this cellular therapy has been the subject of preliminary trials in children. However, this approach seems to present too many disadvantages to be applicable to the treatment of muscle diseases. In fact, since the migratory capacities of the precursor cells are reduced to a few millimeters, the cellular implantation of these latter would necessitate millions of injections requiring hours of anaesthesia. Inevitably, there would be the risk of immunological problems leading to rejection phenomena occurring, as in the case of very many grafts. In addition, the treatment of Duchenne's muscular dystrophy (DMD) not only requires making contact with the

REPLACEMENT SHEET

12 FEB 1997

skeletal muscles but also with the myocardial cells; the difficulties likely to be encountered in implanting precursors of muscle cells in the myocardium can easily be imagined. Consequently, cellular therapy hardly seems to be appropriate for the treatment of diseased cells showing such dissemination in the organism.


Gene therapy by direct in vivo introduction of nucleic acids into the interior of organs is an attractive method on account of its simplicity, but its development is confronted with a number of obstacles. In particular, the expression of genes in the muscles remains localised at the site of injection (Wolff, J.A. et al., mentioned above) and seems to be of quite limited duration, particularly in cardiac muscle (Acsadi, G. et al., mentioned above).

The aim of the present invention is precisely to make possible the introduction of a very large number of nucleic acids into a considerable number of muscle cells (up to 50% or more) of a human or animal organism, whether these muscle cells be those of skeletal muscle or those of the myocardium.

The present invention relates more particularly to the transport of nucleic acids to target muscle cells by the blood, while protecting these nucleic acids against attack by various blood constituents.

Another aim of the present invention is to make available to the public pharmaceutical compositions which make possible the treatment of muscle diseases, and more particularly genetic diseases of the muscle system, or also diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleic acids, these products being secreted by the said muscle cells.

The present invention follows from the discovery made by the inventors of the fact that beta-galactosidase activity is found in many tissues after injection into mice of recombinant vectors of viral origin, more




particularly of adenoviral origin, into the genome of which the gene coding for beta-galactosidase has been inserted. Such tissues include the lungs, liver, intestine, heart and the skeletal muscles. The expression of the gene for beta-galactosidase is constant with time, since the proportion of blue-coloured cells (colour obtained subsequent to gene expression) in the muscle tissue is more or less the same from one month to the next.

Figure 1 shows an example of the construction of a recombinant vector according to the invention and corresponding to a type Ad5 adenovirus, into the genome of which the gene for beta-galactosidase has been inserted under the control of the RSV promoter.

The subject of the present invention is the use of recombinant vectors of viral origin, incapable of replication and likely to be recognized by the receptors of human and animal muscle cell which can be infected by these viruses, these vectors being additionally modified by a nucleic acid insert containing a nucleotide sequence which codes for a polypeptide sequence, the expression of which in the said muscle cells is sought, this sequence being under the control of a promoter recognized by the polymerases of these cells, for the production of drug compositions which can be administered by the general route, particularly the intravenous or intraarterial route, and designed for the treatment of either diseases affecting muscle cells or diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleic acids and secreted by the said muscle cells.

The adenoviruses, in particular the human adenoviruses type 2 or 5 represent particularly preferred vectors in the framework of the present invention by virtue in particular of the large size of the foreign DNA fragment which it is possible to insert into the genome of these viruses.

Advantageously, the above-mentioned nucleic acid insert is included in a defective genome of an adenovirus, this genome lacking essential



sequences necessary for the replication of these adenoviruses, and more particularly the EA and EB transactivators; nonetheless, this genome preferentially includes all of those essential sequences necessary for the encapsidation of these adenoviruses.

The promoter used may be an endogenous promoter (for example, an early or late promoter of the adenoviruses used) or an exogenous promoter.

It will be advantageous to have recourse to strong promoters, for example one having about the same strength as the promoter contained in the LTR (Long Terminal Repeat) of RSV (Rous Sarcoma Virus).

As examples of other promoters whose use may be considered, mention should be made of:

- the promoter of the IE gene of CMV (cytomegalovirus)
- the MMTV (Mouse Mammary umor Virus) inducible promoters or metallothionine promoters.

The strength of the promoter which is used may be estimated in assays similar to those which are described in the examples which follow, for example by replacing the promoter under study in the vectors of these examples by the promoter contained in the LTR or RSV and by the evaluation of the intensity of expression of the marker obtained, an intensity which can then be compared with that obtained with the promoter of LTR of RSV.

The amount of vectors administered to the organism is advantageously chosen so as to overwhelm the immune system of the organism into which they are injected.

Advantageously, the route of administration selected in the framework of the present invention is the intravenous or intraarterial route.

Among the diseases affecting muscle cells mentioned above, mention may be made of genetic diseases such as muscular dystrophy.

REPLACEMENT SHEET

12 FEB 1997


Consequently, the nucleic acid inserted into the genome of the viral vector and the diffusion of which into the muscle mass is desired, comprises a nucleotide sequence coding for a polypeptide capable of treating the disease in question, and more particularly of playing the role in the muscle cell of the polypeptide normally present in a healthy cell, but the deficiency of which is due either to an abnormally low level or the complete failure of the production of this polypeptide, or to an error in its amino acid sequence which results from genetic anomalies in its coding nucleotide sequence.

Vectors according to the invention used to produce a medicine designed for the treatment of muscular dystrophy are more particularly characterized in that the nucleic acid insert is constituted by all or part of a healthy gene for dystrophin. The introduction of the entire gene for dystrophin or even of any part of this gene which codes for a polypeptide conserving an activity similar to that of the whole protein can be carried out in accordance with a method identical with that described hereafter for the introduction of the gene for beta-galactosidase.

As examples of diseases other than muscle diseases, susceptible to treatment in the framework of the present invention, mention may be made of the thromboses originating from infarctuses or also phlebitis.

Vectors according to the invention used to produce a drug, designed for the treatment of thromboses and for the prevention of infarcts and phlebitis are more particularly characterized in that the nucleic acid insert comprises a nucleotide sequence coding for a thrombolytic substance. The latter sequence is advantageously preceded by a signal sequence which codes for a peptide signal which ensures the secretion of the thrombolytic substance outside the muscle cell.

The invention also relates to any recombinant vector characterized in that it is constituted of the defective genome of an adenovirus comprising,




nonetheless, all of the essential sequences necessary for the encapsidation of this adenovirus, and into which is inserted a recombinant nucleic acid, the diffusion of which is desired in the muscle mass, this nucleic acid being placed under the control of a promoter capable of being recognized by the polymerases of the muscle cells, in particular by the strong promoter of the E1A early region of the genome of the adenoviruses.

A preferred recombinant vector of the invention is characterized in that this recombinant nucleic acid is constituted by all or part of the gene for dystrophin.

The invention also relates to pharmaceutical compositions consisting one or more recombinant vectors such as those described above, in combination with a pharmaceutically acceptable vehicle.

The subject of the invention is also a procedure for producing the recombinant vectors described above which comprises, after the construction stage itself of these vectors by the introduction of the nucleic acid insert into their genome, a transformation step of transformable cell lines of higher eukaryotes (particularly of human or animal origin), themselves carrying a distinct nucleotide sequence capable of complementing the part of the genome of the adenovirus essential for the replication thereof and which the above-mentioned vector lacks, the said distinct sequence being preferably incorporated into the genome of the cells of the said cell line.

As a preferred example of such cell lines, mention should be made of line 293, a human embryonic kidney which contains, integrated into its genome, the first eleven percent of the lefthand end of the genome of an Ad5. This portion complements defective recombinant viruses which bear deletions in this region. Such a production procedure is more particularly described in the European patent application No. 0 185 573 of 20/11/85.



After transformation of these cell lines, the vectors which are thus multiplied are recovered and purified.


The present invention will be illustrated more particularly with the aid of the detailed description which follows of the construction of recombinant adenovirus vectors comprising the gene coding for beta-galactosidase, and of the properties of this adenovirus vector.

1. Construction of the recombinant adenovirus, Ad-RSV-beta-gal, by means of in vivo recombination.

This recombinant adenovirus was constructed by homologous recombination between a suitable plasmid and the genome of a type 5 (Ad5) adenovirus. In this construction, the gene for beta-galactosidase is placed under the control of the RSV (Rous Sarcoma Virus) promoter. The plasmid pAdRSV ' β gal' contains the PvuII segment of the lefthand end of the Ad5 (segment situated between the positions 0 and 1.3 of the plasmid in Figure 1) comprising the inverted terminal repeat, the origin of replication, encapsidation signals and the amplifier Ela. This fragment is followed by a nlslacZ gene (described in Bonnerot, C; et al., Proc. Natl. Acad. Sci. USA, 1987, 84, 6795-6799) which codes for beta-galactosidase, and by a fragment of the adenovirus Ad5 situated between the positions 9.4 and 17 of the plasmid of Figure 1.

The values of the positions 1.3, 9.4 and 17 indicated above are units indicating the number of base pairs included within these fragments, one unit representing 360 base pairs.

The Ad5 sequence situated between the above-mentioned positions 9.4 and 17 allows recombination with the adenovirus dl324 treated by the restriction enzyme Cla I (corresponding to a deletion mutant E3; the deletion being made between the positions 78.4 and 84.3 of the genome of the adenovirus shown in Figure 1), after transfection of 293 cells (human embryonic kidney cells transformed by the adenovirus and mentioned




above) in order to generate the recombinant vector Ad-RSV-beta_{gal}. The nls_{lacZ} gene is controlled by the RSV LTR promoter and possesses the polyadenylation signal of the SV40 virus. The recombinant virus thus obtained is incapable of replicating on account of the deletion of the E1 genes.

2. Study of the transfer of the gene to the organs of the mouse through the intermediary of the adenovirus.

Four day old Balb/C mice are given an intravenous injection of 20-40 microliters of highly purified recombinant adenovirus Ad-RSV-beta_{gal} (10^9 plaque-forming units: PFU/ml), the organs were excised 15 days after the injection and treated with 4% paraformaldehyde in a phosphate buffer for 30 minutes. After being rinsed, the organs were incubated overnight at 30°C in a X-gal solution. The whole organs were then frozen and treated appropriately so that cryosections (10 micrometers thick) could be prepared and these sections were stained with the aid of hematoxylin and eosin.

The demonstration by means of histochemical staining in the manner indicated above of beta-galactosidase activity in the sections prepared indicates the presence of the gene inserted into the adenovirus vector in the cells of the excised organs.


The macroscopic examination of the heart as well as the skeletal muscles excised from these treated mice reveals the great efficiency with which this gene transfer was made after only one injection of the recombinant adenovirus. The significance of the choice of the intravenous route resides in the fact that the viral vector is not concentrated in any particular zone of the muscle tissue but, conversely, it is favourably distributed throughout the muscle mass. The histochemical staining leads to estimates that the number of transformed cells in some zones attains as much as 50% of the number of muscle cells present in this zone.



The expression of beta-galactosidase in the myocardium as well as in the skeletal muscles is perfectly stable. It was possible to observe positive stains 15, 33, 55, 66, 90, 127 and 150 days after the injection of the recombinant adenovirus. The expression of the gene seems to be constant as a function of time since the proportion of blue cells in the muscle tissues seem to be more or less the same from one month to the next.

The analysis of isolated muscle fibers reveals that a single fiber is likely to offer many "centers of expression".

Analyses by (Southern) immunoblot performed on the heart of a treated mouse have led to the demonstration of an intense and unique band at 35 kbp indicating that the viral DNA introduced into the muscle cells is essentially extrachromosomal.



This Sheet Has Been Replaced

10



CLAIMS

THIS SHEET HAS BEEN
REPLACED

1. Use of recombinant vectors of viral origin, incapable of replication and capable of being recognized by the receptors of human and animal muscle cells which can be infected with these viruses, these viruses being in addition modified by a nucleic acid insert containing a nucleotide sequence coding for a polypeptide sequence, the expression of which in the said muscle cells is sought this sequence being under the control of a promoter recognized by the polymerases of these cells for the production of a drug composition which can be administered by the general route, in particular the intravenous or intraarterial route, and is designed for the treatment of either diseases affecting the muscle cells or diseases, the localization of which in the organism makes them accessible to the expression products of the above-mentioned nucleotide sequence secreted by said muscle cells.
2. Use of vectors according to Claim 1, characterized in that these vectors are selected from defective adenoviruses, the genomes of which lack essential sequences necessary for the replication of these adenoviruses, and more particularly the EA and EB transactivators.
3. Use of vectors according to Claim 1 or Claim 2, characterized in that the nucleic acid insert is included in a defective adenovirus genome comprising nonetheless all the essential sequences necessary for the encapsidation of these adenoviruses.
4. Use of vectors according to one of the Claims 1 to 3, characterized in that the nucleic acid insert is constituted by all or part of a healthy gene for dystrophin.
5. Use of vectors according to one of the Claims 1 to 4 for the production of a medicine designed for the treatment of Duchenne's muscular dystrophy.



* C L M S *

REPLACEMENT SHEET

12 FEB 1997



THIS SHEET HAS BEEN
REPLACED

6. Use of vectors according to any one of the Claims 1 to 3 for the production of drug compositions for the treatment of cardiac diseases, characterized in that the nucleic acid insert codes for a protein or polypeptide having thrombolytic properties.

7. Recombinant vector characterized in that it is constituted by a defective genome of an adenovirus, nonetheless comprising all of the essential sequences necessary for the encapsidation of this adenovirus, and in which is inserted a recombinant nucleic acid, the diffusion of which into the muscle mass is sought, this nucleic acid being placed under the control of a promoter capable of being recognized by the polymerases of the muscle cells, in particular the strong promoter of the E1A early region of the genome of the adenoviruses.

8. Recombinant vector according to Claim 7, characterized in that the nucleic acid insert codes for a protein or polypeptide having thrombolytic properties.

9. Pharmaceutical composition containing a recombinant vector according to Claim 7 or Claim 8, in combination with a pharmaceutically acceptable vehicle.



REPLACEMENT SHEET

12 FEB 1997

ABSTRACT**VIRAL RECOMBINANT VECTORS FOR EXPRESSION IN MUSCLE CELLS**

Non-replicable viral recombinant vectors which are recognizable by muscle cell receptors, and furthermore modified by an insertion nucleic acid coding for a polypeptide sequence to be expressed in said muscle cell, are used to obtain a drug for treating muscle cell diseases which by virtue of their location in the body, are accessible to the products of the expression of the above mentioned nucleotide sequence, as secreted by said muscle cells. A method for producing said vectors, vectors such as those described above, and their use in pharmaceutical compositions are also provided.

Figure 1





FIGURE 1



REPLACEMENT SHEET
12 FEB 1997

THIS SHEET HAS BEEN
REPLACED



10

CLAIMS

REPLACEMENT SHEETS SG

- ☐ Description : paged to paged
☒ Claim(s) : paged 10 to paged 11..
☐ Drawing(s) : paged to paged
☐ Abstract : paged to paged

DATE OF RECEIPT 31/8/98

1. Use of recombinant viral vectors comprising a nucleic acid sequence encoding a polypeptide for the production of a drug composition which is administered by the intravenous or intraarterial route for the treatment of diseases affecting the muscle cells, said nucleotide sequence is under the control of a promoter recognized by polymerases of said muscle cells and wherein said polypeptide is expressed in said muscle cells.
2. Use of vectors according to Claim 1, characterized in that these vectors are selected from defective adenoviruses, the genomes of which lack the essential sequences necessary for the replication of the adenoviruses.
3. Use of vectors according to Claim 2, wherein said defective adenoviruses lack the E1A and E1B transactivators, and where appropriate, the E3 region.
4. Use of vectors according to Claim 1, wherein the nucleic acid sequence is included in a defective adenovirus genome comprising all of the essential sequences necessary for the encapsidation of these adenoviruses.
5. Use of vectors according to Claim 1, wherein the nucleic acid sequence is constituted by all or part of a gene for dystrophin.
6. Use of vectors according to Claim 5 for the treatment of Duchenne's muscular dystrophy.
7. Use of vectors according to Claim 1, wherein the nucleic acid sequence codes for a protein or polypeptide having thrombolytic properties.
8. Use of vectors according to Claim 7 for the treatment of cardiac diseases.

This Sheet Has Been Replaced





9. A recombinant vector comprising a defective genome of an adenovirus, comprising all of the essential sequences necessary for the encapsidation of said adenovirus, and in which is inserted a nucleic acid sequence under the control of a promoter selected from the group of: a promoter from the Rous Sarcoma Virus Long Terminal Repeat, a promoter of the IE gene of Cytomegalovirus, a Mouse Mammary Tumor Virus inducible promoter and an E1A early promoter.

10. The recombinant vector according to claim 9, wherein said promoter is the strong promoter of the E1A early region of the genome of the adenoviruses.

11. The recombinant vector according to claim 9, wherein the nucleic acid sequence is constituted by all or part of a gene for dystrophin.


12. The recombinant vector according to claim 9, wherein the nucleic acid sequence codes for a protein or polypeptide having thrombolytic properties.

13. A pharmaceutical composition comprising the recombinant vector according to any one of Claims 9 to 12.

14. A method for producing a recombinant vector according to any one of Claims 9 to 12 comprising the steps of:

(a) transforming a higher eukaryotic cell line carrying a distinct nucleotide sequence capable of complementing the part of the adenovirus genome which is lacking in said vector and which is essential for its replication, said distinct nucleotide sequence being preferably incorporated into the genome of the cells of said cell line; and

(b) recovering the recombinant vector from the culture of said cell line.





10

CLAIMS**REPLACEMENT SHEETS SG**

- ☐ Description : paged to paged
☒ Claim(s) : paged 10 to paged 11a
☐ Drawing(s) : paged to paged
☐ Abstract : paged to paged

DATE OF RECEIPT 4/2/99


1. Use of nonreplicative recombinant viral vectors which are capable of being recognized by the receptors of human and animal target muscle cells and are capable of infecting these target cells comprising a nucleic acid sequence encoding a polypeptide for the production of a drug composition which is administered by the intravenous or intraarterial route for the treatment of diseases affecting the muscle cells, said nucleotide sequence is under the control of a promoter recognized by polymerases of said muscle cells and wherein said polypeptide is expressed in said muscle cells.
2. Use of vectors according to Claim 1, characterized in that these vectors are selected from defective adenoviruses, the genomes of which lack the essential sequences necessary for the replication of the adenoviruses.
3. Use of vectors according to Claim 2, wherein said defective adenoviruses lack the E1A and E1B transactivators, and where appropriate, the E3 region.
4. Use of vectors according to Claim 1, wherein the nucleic acid sequence is included in a defective adenovirus genome comprising all of the essential sequences necessary for the encapsidation of these adenoviruses.
5. Use of vectors according to Claim 1, wherein the nucleic acid sequence is constituted by all or part of a functional gene for dystrophin.
6. Use of vectors according to Claim 5 for the treatment of Duchenne's muscular dystrophy.
7. Use of vectors according to Claim 1, wherein the nucleic acid sequence codes for a protein or polypeptide having thrombolytic properties.


REPLACEMENT SHEET

U 4 FEB 1999



8. Use of vectors according to Claim 7 for the treatment of cardiac diseases.
9. A recombinant vector comprising a defective genome of an adenovirus, comprising all of the essential sequences necessary for the encapsidation of said adenovirus, and in which is inserted a nucleic acid sequence under the control of a promoter selected from the group of: a promoter from the Rous Sarcoma Virus Long Terminal Repeat, a promoter of the IE gene of Cytomegalovirus, a Mouse Mammary Tumor Virus inducible promoter and an E1A early promoter wherein said inserted nucleic acid sequence is expressed in target muscle cells.
10. The recombinant vector according to claim 9, wherein said promoter is the strong promoter of the E1A early region of the genome of the adenoviruses.
11. The recombinant vector according to claim 9, wherein the nucleic acid sequence is constituted by all or part of a functional gene for dystrophin.
12. The recombinant vector according to claim 9, wherein the nucleic acid sequence codes for a protein or polypeptide having thrombolytic properties.
13. A pharmaceutical composition comprising the recombinant vector according to any one of Claims 9 to 12.
14. A method for producing a recombinant vector according to any one of Claims 9 to 12 comprising the steps of:
 - (a) producing a recombinant viral construct by inserting a nucleic acid sequence encoding a product to be expressed in target muscle cells into a defective genome of an adenovirus;





11a

(b) transforming a higher eukaryotic cell line carrying a distinct nucleotide sequence capable of complementing the part of the adenovirus genome which is lacking in said vector and which is essential for its replication, said distinct nucleotide sequence being preferably incorporated into the genome of the cells of said cell line; and

(c) recovering the recombinant vector from the culture of said cell line.

